You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmiodarone
Accession NumberDB01118  (APRD00288)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [PubChem]
Structure
Thumb
Synonyms
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Amiodarona
Amiodarone
Amiodaronum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodaronetablet200 mgoralSanis Health Inc2011-06-10Not applicableCanada
Amiodaronetablet200 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Amiodaronetablet200 mgoralSorres Pharma Inc2009-06-232014-06-20Canada
Amiodarone for Injection 50mg/mlsolution50 mgintravenousTeva Canada Limited2004-04-21Not applicableCanada
Amiodarone Hydrochloride for Injectionsolution50 mgintravenousHospira Healthcare Corporation2002-08-29Not applicableCanada
Amiodarone Hydrochloride for Injectionliquid50 mgintravenousSandoz Canada Incorporated2000-06-14Not applicableCanada
Amiodarone Hydrochloride for Injectionsolution50 mgintravenousFresenius Kabi Canada Ltd2002-04-23Not applicableCanada
Amiodarone Hydrochloride Injectionsolution50 mgintravenousMylan Pharmaceuticals Ulc2012-10-242016-07-06Canada
Amiodarone Omegasolution50 mgintravenousOmega Laboratories LtdNot applicableNot applicableCanada
Amiodarone Syringesolution50 mgintravenousSandoz Canada Incorporated2015-08-12Not applicableCanada
Ava-amiodaronetablet200 mgoralAvanstra Inc2011-09-152014-08-21Canada
Cordaronetablet200 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1985-12-01Not applicableUs
Cordaronetablet200 mgoralPfizer Canada Inc1994-12-312016-07-12Canada
Cordarone Intravenous - Liq IV 50mg/mlliquid50 mgintravenousWyeth Ayerst Canada Inc.1995-12-312003-04-17Canada
Cordarone Tab 200mgtablet200 mgoralAyerst Laboratories1986-12-311996-09-10Canada
Dom-amiodaronetablet100 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-amiodaronetablet200 mgoralDominion Pharmacal2004-04-15Not applicableCanada
Jamp-amiodaronesolution50 mgintravenousJamp Pharma CorporationNot applicableNot applicableCanada
Mylan-amiodaronetablet200 mgoralMylan Pharmaceuticals Ulc1999-08-04Not applicableCanada
Mylan-amiodarone Sterile Concentrate, BPsolution50 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Nexteroneinjection, solution1.5 mg/mLintravenousBaxter Healthcare Corporation2010-11-16Not applicableUs
Nexteroneinjection, solution1.8 mg/mLintravenousBaxter Healthcare Corporation2010-11-16Not applicableUs
Ntp-amiodaronetablet200 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-amiodaronetablet200 mgoralNu Pharm IncNot applicableNot applicableCanada
Pendo-amiodaronetablet200 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-amiodaronetablet200 mgoralPharmel Inc2002-05-27Not applicableCanada
PHL-amiodaronetablet100 mgoralPharmel IncNot applicableNot applicableCanada
PMS-amiodaronetablet100 mgoralPharmascience Inc2007-04-03Not applicableCanada
PMS-amiodaronetablet200 mgoralPharmascience Inc2000-07-28Not applicableCanada
Pro-amiodarone - 200tablet200 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Ratio-amiodaronetablet200 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-05-122014-09-19Canada
Ratio-amiodarone I.V.liquid50 mgintravenousRatiopharm Inc Division Of Teva Canada Limited2000-09-272008-08-01Canada
Riva-amiodaronetablet200 mgoralLaboratoire Riva Inc2003-03-05Not applicableCanada
Sandoz Amiodaronetablet200 mgoralSandoz Canada Incorporated2001-08-21Not applicableCanada
Teva-amiodaronetablet200 mgoralTeva Canada Limited1999-03-29Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HCltablet200 mg/1oralLibertas Pharma, Inc.2013-01-01Not applicableUs
Amiodarone HCltablet400 mg/1oralLibertas Pharma, Inc.2013-01-01Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousREMEDYREPACK INC.2015-08-19Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousGeneral Injectables & Vaccines, Inc2012-06-06Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousHospira, Inc.2013-11-25Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralCardinal Health1998-11-30Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-08-10Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2001-03-30Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralTeva Pharmaceuticals USA Inc1998-11-30Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousSagent Pharmaceuticals2013-07-15Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralCadila Healthcare Limited2009-08-10Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralPhysicians Total Care, Inc.2002-04-22Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralGolden State Medical Supply, Inc.2001-03-30Not applicableUs
Amiodarone Hydrochloridetablet400 mg/1oralAv Kare, Inc.2016-03-18Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousHospira, Inc.2002-10-18Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousAPP Pharmaceuticals, LLC2003-01-28Not applicableUs
Amiodarone Hydrochlorideinjection, solution, concentrate50 mg/mLintravenousGeneral Injectables & Vaccines, Inc.2010-03-01Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousWest ward Pharmaceutical Corp2008-02-25Not applicableUs
Amiodarone Hydrochloridetablet100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2001-03-30Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-11-30Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousMylan Institutional LLC2002-10-14Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralApotex Corp2008-11-06Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-12-23Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralMc Kesson Packaging A Business Unit Of Mc Kesson Corporation2008-03-01Not applicableUs
Amiodarone Hydrochlorideinjection50 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2014-09-02Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralEon Labs, Inc.1998-12-23Not applicableUs
Amiodarone Hydrochlorideinjection50 mg/mLintravenousWockhardt Limited2008-10-30Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralMc Kesson Contract Packaging2012-01-03Not applicableUs
Amiodarone Hydrochloridetablet300 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2003-12-02Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2011-04-12Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2014-08-01Not applicableUs
Amiodarone Hydrochlorideinjection, solution50 mg/mLintravenousHospira, Inc.2013-11-25Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2015-05-15Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralRebel Distributors Corp2009-08-10Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Amiodarone Hydrochlorideinjection50 mg/mLintravenousWockhardt Limited2008-10-30Not applicableUs
Amiodarone Hydrochloridetablet400 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2002-11-29Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralCardinal Health2009-09-25Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralMylan Institutional Inc.1999-11-01Not applicableUs
Amiodarone Hydrochloridetablet200 mg/1oralAmerican Health Packaging2009-09-25Not applicableUs
Apo-amiodarone Tabletstablet200 mgoralApotex Inc2003-09-05Not applicableCanada
Paceronetablet400 mg/1oralUpsher Smith Laboratories, Inc.2000-06-30Not applicableUs
Paceronetablet200 mg/1oralCardinal Health2011-01-19Not applicableUs
Paceronetablet200 mg/1oralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Paceronetablet200 mg/1oralPhysicians Total Care, Inc.2008-10-22Not applicableUs
Paceronetablet200 mg/1oralUpsher Smith Laboratories, Inc.2011-01-19Not applicableUs
Paceronetablet200 mg/1oralAphena Pharma Solutions Tennessee, Llc2011-01-19Not applicableUs
Paceronetablet200 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-04-28Not applicableUs
Paceronetablet100 mg/1oralUpsher Smith Laboratories, Inc.2011-01-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClinjection, solution1.8 mg/mLintravenousCantrell Drug Company2011-08-01Not applicableUs
International Brands
NameCompany
Amio-Aqueous IVNot Available
AratacNot Available
ArycorNot Available
AtlansilNot Available
TachyraNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Amiodarone Hydrochloride
Thumb
  • InChI Key: ITPDYQOUSLNIHG-UHFFFAOYSA-N
  • Monoisotopic Mass: 681.000358378
  • Average Mass: 681.773
DBSALT000355
Categories
UNIIN3RQ532IUT
CAS number1951-25-3
WeightAverage: 645.3116
Monoisotopic: 645.023680639
Chemical FormulaC25H29I2NO3
InChI KeyInChIKey=IYIKLHRQXLHMJQ-UHFFFAOYSA-N
InChI
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
IUPAC Name
{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine
SMILES
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzofurans
Sub ClassNot Available
Direct ParentBenzofurans
Alternative Parents
Substituents
  • Benzofuran
  • Acetophenone
  • Aryl ketone
  • 3-aroylfuran
  • Phenol ether
  • Benzoyl
  • Iodobenzene
  • Halobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl iodide
  • Aryl halide
  • Heteroaromatic compound
  • Furan
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organoiodide
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationIntravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
PharmacodynamicsAmiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.
Mechanism of actionThe antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.
Related Articles
AbsorptionSlow and variable (about 20 to 55% of an oral dose is absorbed).
Volume of distributionNot Available
Protein binding>96%
Metabolism

Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

SubstrateEnzymesProduct
Amiodarone
N-desethylamiodaroneDetails
Route of eliminationAmiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.
Half life58 days (range 15-142 days)
Clearance
  • 90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)]
  • 100 mL/h/kg [Normal subjects > 65 yrs]
  • 150 mL/h/kg [younger subjects]
  • 220 and 440 mL/h/kg [patients with VT and VF]
ToxicityIntravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Amiodarone Action PathwayDrug actionSMP00665
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Potassium voltage-gated channel subfamily H member 2
Gene symbol: KCNH2
UniProt: Q12809
Not AvailableMiRP1KCNE2Channels formed with mutant MiRP1 subunits and HERG showed slower activation, faster deactivation, and increased drug sensitivity and is associated with cardiac arrhythmia.10219239
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8615
Caco-2 permeable+0.66
P-glycoprotein substrateSubstrate0.8044
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5099
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7188
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8615
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.7696
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5932
hERG inhibition (predictor II)Inhibitor0.7638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous50 mg/mL
Injection, solutionintravenous50 mg/mL
Injection, solution, concentrateintravenous50 mg/mL
Tabletoral300 mg/1
Liquidintravenous50 mg
Solutionintravenous50 mg
Tabletoral200 mg/1
Injection, solutionintravenous1.5 mg/mL
Injection, solutionintravenous1.8 mg/mL
Tabletoral100 mg/1
Tabletoral400 mg/1
Tabletoral100 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Amiodarone hcl powder38.98USD g
Pacerone 100 mg tablet7.58USD tablet
Pacerone 400 mg tablet7.43USD tablet
Amiodarone hcl 400 mg tablet6.32USD tablet
Cordarone 200 mg tablet4.78USD tablet
Pacerone 200 mg tablet3.53USD tablet
Amiodarone hcl 200 mg tablet3.37USD tablet
Cordarone 200 mg Tablet2.32USD tablet
Apo-Amiodarone 200 mg Tablet1.3USD tablet
Mylan-Amiodarone 200 mg Tablet1.3USD tablet
Novo-Amiodarone 200 mg Tablet1.3USD tablet
Pms-Amiodarone 200 mg Tablet1.3USD tablet
Ratio-Amiodarone 200 mg Tablet1.3USD tablet
Sandoz Amiodarone 200 mg Tablet1.3USD tablet
Amiodarone 150 mg/3 ml vial0.83USD ml
Pms-Amiodarone 100 mg Tablet0.72USD tablet
Amiodarone 900 mg/18 ml vial0.59USD ml
Amiodarone 450 mg/9 ml vial0.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5134127 No1993-01-232010-01-23Us
US6869939 No2002-05-042022-05-04Us
US7635773 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156Tondeur, R. and Binon, F.; U.S. Patent 3,248,401; April 26,1966; assigned to Societe Beige de I'Azote et des Produits Chimiques du Marly, SA, Belgium.
water solubilityLowNot Available
logP7.57AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00476 mg/mLALOGPS
logP7.24ALOGPS
logP7.64ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.68 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity145.05 m3·mol-1ChemAxon
Polarizability56.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3248401
General References
  1. DELTOUR G, BINON F, TONDEUR R, GOLDENBERG C, HENAUX F, SION R, DERAY E, CHARLIER R: [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:247-54. [PubMed:14026835 ]
  2. CHARLIER R, DELTOUR G, TONDEUR R, BINON F: [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255-64. [PubMed:14020244 ]
  3. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657-67. [PubMed:5485142 ]
  4. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934-44. [PubMed:793369 ]
  5. Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV: Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957-64. [PubMed:6613843 ]
External Links
ATC CodesC01BD01
AHFS Codes
  • 24:04.04.20
PDB EntriesNot Available
FDA labelDownload (545 KB)
MSDSDownload (51.8 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Amiodarone.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Amiodarone.
AbirateroneThe serum concentration of Amiodarone can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Amiodarone.
AcebutololAmiodarone may increase the bradycardic activities of Acebutolol.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Amiodarone.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Amiodarone.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Amiodarone.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Amiodarone.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Amiodarone.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Amiodarone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Amiodarone.
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.
AjmalineAmiodarone may increase the QTc-prolonging activities of Ajmaline.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Amiodarone.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Amiodarone.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Amiodarone.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Amiodarone.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Amiodarone.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Amiodarone.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Amiodarone.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Amiodarone.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Amiodarone.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Amiodarone.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Amiodarone.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Amiodarone.
AlprenololAmiodarone may increase the bradycardic activities of Alprenolol.
AmantadineAmantadine may increase the QTc-prolonging activities of Amiodarone.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Amiodarone.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Amiodarone.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Amiodarone.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Amiodarone.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Amiodarone.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Amiodarone.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Amiodarone.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Amiodarone.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Amiodarone.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Amiodarone.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Amiodarone.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Amiodarone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Amiodarone.
ApremilastThe metabolism of Apremilast can be decreased when combined with Amiodarone.
AprepitantThe serum concentration of Amiodarone can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Amiodarone.
AprindineThe metabolism of Aprindine can be decreased when combined with Amiodarone.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Amiodarone.
ArformoterolArformoterol may increase the QTc-prolonging activities of Amiodarone.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Amiodarone.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Amiodarone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Amiodarone.
ArmodafinilThe metabolism of Amiodarone can be decreased when combined with Armodafinil.
ArotinololAmiodarone may increase the bradycardic activities of Arotinolol.
Arsenic trioxideAmiodarone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherAmiodarone may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amiodarone resulting in a loss in efficacy.
AsenapineAmiodarone may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Amiodarone.
AtazanavirThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Amiodarone.
AtenololAmiodarone may increase the bradycardic activities of Atenolol.
AtomoxetineThe metabolism of Amiodarone can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Amiodarone.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Amiodarone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amiodarone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Amiodarone.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Amiodarone.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Amiodarone.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Amiodarone.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Amiodarone.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Amiodarone.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Amiodarone.
BefunololAmiodarone may increase the bradycardic activities of Befunolol.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Amiodarone.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Amiodarone.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Amiodarone.
BepridilThe metabolism of Bepridil can be decreased when combined with Amiodarone.
BeractantAmiodarone may increase the bradycardic activities of Beractant.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Amiodarone.
BetaxololAmiodarone may increase the bradycardic activities of Betaxolol.
BevantololAmiodarone may increase the bradycardic activities of Bevantolol.
BexaroteneThe serum concentration of Amiodarone can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Amiodarone.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Amiodarone.
BisoprololAmiodarone may increase the bradycardic activities of Bisoprolol.
BoceprevirThe serum concentration of Amiodarone can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Amiodarone.
BopindololAmiodarone may increase the bradycardic activities of Bopindolol.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.
BortezomibThe metabolism of Amiodarone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Amiodarone can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.
BretyliumBretylium may increase the bradycardic activities of Amiodarone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Amiodarone.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Amiodarone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Amiodarone.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.
BufuralolAmiodarone may increase the bradycardic activities of Bufuralol.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Amiodarone.
BupranololAmiodarone may increase the bradycardic activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.
BupropionThe metabolism of Bupropion can be decreased when combined with Amiodarone.
BuserelinBuserelin may increase the QTc-prolonging activities of Amiodarone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Amiodarone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Amiodarone.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Amiodarone.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Amiodarone.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Amiodarone.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Amiodarone.
CaffeineThe metabolism of Amiodarone can be decreased when combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Amiodarone.
CalfactantAmiodarone may increase the bradycardic activities of Calfactant.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Amiodarone.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Amiodarone.
CandesartanThe metabolism of Candesartan can be decreased when combined with Amiodarone.
CapecitabineThe metabolism of Amiodarone can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Amiodarone.
CarbamazepineThe metabolism of Amiodarone can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Amiodarone.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Amiodarone.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Amiodarone.
CarteololAmiodarone may increase the bradycardic activities of Carteolol.
CarvedilolAmiodarone may increase the bradycardic activities of Carvedilol.
CelecoxibThe metabolism of Amiodarone can be decreased when combined with Celecoxib.
CeliprololAmiodarone may increase the bradycardic activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Amiodarone.
CeritinibAmiodarone may increase the bradycardic activities of Ceritinib.
CeritinibCeritinib may increase the QTc-prolonging activities of Amiodarone.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Amiodarone.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Amiodarone.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Amiodarone.
ChloramphenicolThe metabolism of Amiodarone can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Amiodarone.
ChloroquineChloroquine may increase the QTc-prolonging activities of Amiodarone.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Amiodarone.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Amiodarone.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Amiodarone.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Amiodarone.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Amiodarone.
CholestyramineThe bioavailability of Amiodarone can be decreased when combined with Cholestyramine.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Amiodarone.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Amiodarone.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Amiodarone.
CimetidineThe metabolism of Amiodarone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Amiodarone.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Amiodarone.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Amiodarone.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Amiodarone.
CisaprideCisapride may increase the QTc-prolonging activities of Amiodarone.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Amiodarone.
CitalopramCitalopram may increase the QTc-prolonging activities of Amiodarone.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Amiodarone.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Amiodarone.
ClemastineThe metabolism of Amiodarone can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Amiodarone.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Amiodarone.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Amiodarone.
ClobazamThe metabolism of Amiodarone can be decreased when combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Amiodarone.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Amiodarone.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Amiodarone.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Amiodarone.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Amiodarone.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Amiodarone.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Amiodarone.
ClonidineClonidine may increase the bradycardic activities of Amiodarone.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy.
ClopidogrelThe metabolism of Amiodarone can be decreased when combined with Clopidogrel.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Amiodarone.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Amiodarone.
ClotrimazoleThe metabolism of Amiodarone can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Amiodarone.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Amiodarone.
CobicistatThe serum concentration of Amiodarone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amiodarone.
CocaineThe metabolism of Cocaine can be decreased when combined with Amiodarone.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.
Coenzyme Q10The metabolism of Coenzyme Q10 can be decreased when combined with Amiodarone.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Amiodarone.
ColesevelamThe bioavailability of Amiodarone can be decreased when combined with Colesevelam.
ColestipolThe bioavailability of Amiodarone can be decreased when combined with Colestipol.
ConivaptanThe serum concentration of Amiodarone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Amiodarone.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Amiodarone.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Amiodarone.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Amiodarone.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Amiodarone.
CyclosporineThe metabolism of Amiodarone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Amiodarone.
Cyproterone acetateThe serum concentration of Amiodarone can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Amiodarone.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Amiodarone.
DabrafenibThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Amiodarone.
DaclatasvirDaclatasvir may increase the bradycardic activities of Amiodarone.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Amiodarone.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Amiodarone.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.
DapsoneThe metabolism of Dapsone can be decreased when combined with Amiodarone.
DarifenacinThe metabolism of Amiodarone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Amiodarone can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Amiodarone.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Amiodarone.
DasatinibThe serum concentration of Amiodarone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Amiodarone.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Amiodarone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Amiodarone.
DeferasiroxThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Amiodarone.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Amiodarone.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Amiodarone.
DelavirdineThe metabolism of Amiodarone can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Amiodarone.
DesipramineThe metabolism of Desipramine can be decreased when combined with Amiodarone.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Amiodarone.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.
DexamethasoneThe serum concentration of Amiodarone can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Amiodarone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Amiodarone.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Amiodarone.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Amiodarone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Amiodarone.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Amiodarone.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Amiodarone.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Amiodarone.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Amiodarone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amiodarone.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Amiodarone.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Amiodarone.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Amiodarone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Amiodarone.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Amiodarone.
DigoxinDigoxin may increase the bradycardic activities of Amiodarone.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.
DihydroergotamineThe metabolism of Amiodarone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Amiodarone.
DiltiazemThe metabolism of Amiodarone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Amiodarone.
DiphenhydramineThe metabolism of Amiodarone can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Amiodarone.
DisopyramideAmiodarone may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Amiodarone.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Amiodarone.
DofetilideDofetilide may increase the QTc-prolonging activities of Amiodarone.
DolasetronDolasetron may increase the QTc-prolonging activities of Amiodarone.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Amiodarone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.
DomperidoneDomperidone may increase the QTc-prolonging activities of Amiodarone.
DonepezilDonepezil may increase the bradycardic activities of Amiodarone.
DopamineThe metabolism of Dopamine can be decreased when combined with Amiodarone.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Amiodarone.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Amiodarone.
DoxepinDoxepin may increase the QTc-prolonging activities of Amiodarone.
DoxepinThe metabolism of Doxepin can be decreased when combined with Amiodarone.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Amiodarone.
DoxycyclineThe metabolism of Amiodarone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Amiodarone.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.
DronedaroneDronedarone may increase the QTc-prolonging activities of Amiodarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Amiodarone.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Amiodarone.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Amiodarone.
DuloxetineThe metabolism of Amiodarone can be decreased when combined with Duloxetine.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Amiodarone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Amiodarone.
EfavirenzThe serum concentration of Amiodarone can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Amiodarone.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amiodarone.
EliglustatAmiodarone may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Amiodarone.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Amiodarone.
EncainideThe metabolism of Encainide can be decreased when combined with Amiodarone.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Amiodarone.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Amiodarone.
EnzalutamideThe serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Amiodarone.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Amiodarone.
EquilinThe serum concentration of Equilin can be increased when it is combined with Amiodarone.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Amiodarone.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Amiodarone.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Amiodarone.
EribulinEribulin may increase the QTc-prolonging activities of Amiodarone.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Amiodarone.
ErythromycinErythromycin may increase the QTc-prolonging activities of Amiodarone.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Amiodarone.
EscitalopramAmiodarone may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Amiodarone can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Amiodarone.
EsmololAmiodarone may increase the bradycardic activities of Esmolol.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Amiodarone.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Amiodarone.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Amiodarone.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Amiodarone.
EstramustineThe metabolism of Estramustine can be decreased when combined with Amiodarone.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Amiodarone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Amiodarone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Amiodarone.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.
EthanolThe metabolism of Ethanol can be decreased when combined with Amiodarone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Amiodarone.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.
Ethyl biscoumacetateAmiodarone may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Amiodarone.
EtodolacThe metabolism of Etodolac can be decreased when combined with Amiodarone.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Amiodarone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Amiodarone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.
EtravirineThe serum concentration of Amiodarone can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Amiodarone.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Amiodarone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Amiodarone.
EzogabineEzogabine may increase the QTc-prolonging activities of Amiodarone.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Amiodarone.
FamotidineFamotidine may increase the QTc-prolonging activities of Amiodarone.
FelbamateThe metabolism of Felbamate can be decreased when combined with Amiodarone.
FelbamateFelbamate may increase the QTc-prolonging activities of Amiodarone.
FelodipineThe metabolism of Felodipine can be decreased when combined with Amiodarone.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Amiodarone.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Amiodarone.
FinasterideThe metabolism of Finasteride can be decreased when combined with Amiodarone.
FingolimodFingolimod may increase the arrhythmogenic activities of Amiodarone.
FingolimodAmiodarone may increase the bradycardic activities of Fingolimod.
FlecainideFlecainide may increase the QTc-prolonging activities of Amiodarone.
FlecainideThe metabolism of Flecainide can be decreased when combined with Amiodarone.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.
FloxuridineThe metabolism of Amiodarone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Amiodarone can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Amiodarone.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Amiodarone.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Amiodarone.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Amiodarone.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Amiodarone.
FluorouracilThe metabolism of Amiodarone can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Amiodarone.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Amiodarone.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Amiodarone.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Amiodarone.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Amiodarone.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.
FlutamideThe metabolism of Flutamide can be decreased when combined with Amiodarone.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Amiodarone.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Amiodarone.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Amiodarone.
FluvoxamineThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Amiodarone.
FormoterolThe metabolism of Formoterol can be decreased when combined with Amiodarone.
FosamprenavirThe serum concentration of Amiodarone can be increased when it is combined with Fosamprenavir.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Amiodarone.
FosaprepitantThe serum concentration of Amiodarone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Amiodarone.
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Amiodarone.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Amiodarone.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Amiodarone.
Fusidic AcidThe serum concentration of Amiodarone can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Amiodarone.
GalantamineGalantamine may increase the bradycardic activities of Amiodarone.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Amiodarone.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Amiodarone.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Amiodarone.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Amiodarone.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Amiodarone.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Amiodarone.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Amiodarone.
GlipizideThe metabolism of Glipizide can be decreased when combined with Amiodarone.
GlyburideThe metabolism of Glyburide can be decreased when combined with Amiodarone.
GoserelinGoserelin may increase the QTc-prolonging activities of Amiodarone.
GranisetronGranisetron may increase the QTc-prolonging activities of Amiodarone.
GranisetronThe metabolism of Granisetron can be decreased when combined with Amiodarone.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Amiodarone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Amiodarone.
GuanfacineGuanfacine may increase the bradycardic activities of Amiodarone.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Amiodarone.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Amiodarone.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Amiodarone.
HalothaneThe metabolism of Halothane can be decreased when combined with Amiodarone.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Amiodarone.
HistrelinHistrelin may increase the QTc-prolonging activities of Amiodarone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Amiodarone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Amiodarone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Amiodarone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Amiodarone.
IbandronateIbandronate may increase the QTc-prolonging activities of Amiodarone.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Amiodarone.
IbutilideIbutilide may increase the QTc-prolonging activities of Amiodarone.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Amiodarone.
IdelalisibThe serum concentration of Amiodarone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Amiodarone resulting in a loss in efficacy.
IloperidoneAmiodarone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.
ImatinibThe metabolism of Amiodarone can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Amiodarone.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Amiodarone.
ImipramineThe metabolism of Amiodarone can be decreased when combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Amiodarone.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Amiodarone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Amiodarone.
IndapamideThe metabolism of Indapamide can be decreased when combined with Amiodarone.
IndapamideIndapamide may increase the QTc-prolonging activities of Amiodarone.
IndenololAmiodarone may increase the bradycardic activities of Indenolol.
IndinavirThe serum concentration of Amiodarone can be increased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Amiodarone.
indisulamThe metabolism of indisulam can be decreased when combined with Amiodarone.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Amiodarone.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.
IrbesartanThe metabolism of Amiodarone can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Amiodarone.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Amiodarone.
IsavuconazoniumThe metabolism of Amiodarone can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Amiodarone.
IsoniazidThe metabolism of Amiodarone can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.
IsradipineThe metabolism of Amiodarone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Amiodarone.
IvabradineIvabradine may increase the QTc-prolonging activities of Amiodarone.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Amiodarone.
IvacaftorThe serum concentration of Amiodarone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Amiodarone.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Amiodarone.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Amiodarone.
KetamineThe metabolism of Ketamine can be decreased when combined with Amiodarone.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Amiodarone.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Amiodarone.
KetoconazoleThe metabolism of Amiodarone can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.
LabetalolAmiodarone may increase the bradycardic activities of Labetalol.
LacosamideAmiodarone may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Amiodarone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Amiodarone.
LanreotideAmiodarone may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Amiodarone.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Amiodarone.
LapatinibThe metabolism of Amiodarone can be decreased when combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Amiodarone.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Amiodarone.
LeflunomideThe metabolism of Amiodarone can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Amiodarone.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Amiodarone.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Amiodarone.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Amiodarone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Amiodarone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Amiodarone.
LevobunololAmiodarone may increase the bradycardic activities of Levobunolol.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Amiodarone.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Amiodarone.
LevodopaThe metabolism of Levodopa can be decreased when combined with Amiodarone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Amiodarone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Amiodarone.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Amiodarone.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Amiodarone.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Amiodarone.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Amiodarone.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Amiodarone.
LidocaineLidocaine may increase the arrhythmogenic activities of Amiodarone.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Amiodarone.
LisurideThe metabolism of Lisuride can be decreased when combined with Amiodarone.
LithiumLithium may increase the QTc-prolonging activities of Amiodarone.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Amiodarone.
LomustineThe metabolism of Lomustine can be decreased when combined with Amiodarone.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Amiodarone.
LopinavirLopinavir may increase the QTc-prolonging activities of Amiodarone.
LoratadineThe metabolism of Loratadine can be decreased when combined with Amiodarone.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Amiodarone.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Amiodarone.
LosartanThe metabolism of Amiodarone can be decreased when combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Amiodarone.
LovastatinThe metabolism of Amiodarone can be decreased when combined with Lovastatin.
LucinactantAmiodarone may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Amiodarone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Amiodarone can be decreased when it is combined with Lumacaftor.
LumefantrineAmiodarone may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Amiodarone.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Amiodarone.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Amiodarone.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Amiodarone.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Amiodarone.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Amiodarone.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Amiodarone.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Amiodarone.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Amiodarone.
MefloquineMefloquine may increase the QTc-prolonging activities of Amiodarone.
MelatoninThe metabolism of Melatonin can be decreased when combined with Amiodarone.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Amiodarone.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Amiodarone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Amiodarone.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Amiodarone.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.
MestranolThe metabolism of Mestranol can be decreased when combined with Amiodarone.
MethadoneMethadone may increase the QTc-prolonging activities of Amiodarone.
MethadoneThe metabolism of Methadone can be decreased when combined with Amiodarone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Amiodarone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Amiodarone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Amiodarone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Amiodarone.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Amiodarone.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Amiodarone.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.
MethyldopaMethyldopa may increase the bradycardic activities of Amiodarone.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Amiodarone.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Amiodarone.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Amiodarone.
MetipranololAmiodarone may increase the bradycardic activities of Metipranolol.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Amiodarone.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Amiodarone.
MetoprololAmiodarone may increase the bradycardic activities of Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Amiodarone.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Amiodarone.
MevastatinThe metabolism of Mevastatin can be decreased when combined with Amiodarone.
MexiletineThe metabolism of Amiodarone can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Amiodarone.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Amiodarone.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Amiodarone.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Amiodarone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Amiodarone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Amiodarone.
MipomersenAmiodarone may increase the hepatotoxic activities of Mipomersen.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Amiodarone.
MirabegronThe metabolism of Amiodarone can be decreased when combined with Mirabegron.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Amiodarone.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.
MitotaneThe serum concentration of Amiodarone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Amiodarone.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Amiodarone.
ModafinilThe serum concentration of Amiodarone can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Amiodarone.
MoexiprilMoexipril may increase the QTc-prolonging activities of Amiodarone.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Amiodarone.
MontelukastThe metabolism of Montelukast can be decreased when combined with Amiodarone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Amiodarone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amiodarone.
NadololAmiodarone may increase the bradycardic activities of Nadolol.
NafcillinThe serum concentration of Amiodarone can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amiodarone.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Amiodarone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Amiodarone.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Amiodarone.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.
NebivololNebivolol may increase the bradycardic activities of Amiodarone.
NefazodoneThe metabolism of Amiodarone can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Amiodarone can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Amiodarone.
NetupitantThe serum concentration of Amiodarone can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Amiodarone.
NevirapineThe metabolism of Amiodarone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Amiodarone.
NicardipineThe metabolism of Amiodarone can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Amiodarone.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Amiodarone.
NicotineThe metabolism of Nicotine can be decreased when combined with Amiodarone.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Amiodarone.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.
NilotinibNilotinib may increase the QTc-prolonging activities of Amiodarone.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Amiodarone.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Amiodarone.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Amiodarone.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Amiodarone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Amiodarone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Amiodarone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Amiodarone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.
OctreotideOctreotide may increase the bradycardic activities of Amiodarone.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Amiodarone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Amiodarone.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Amiodarone.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.
OlaparibThe metabolism of Amiodarone can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Amiodarone.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Amiodarone.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Amiodarone.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Amiodarone.
OmeprazoleThe metabolism of Amiodarone can be decreased when combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Amiodarone.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Amiodarone.
OrlistatOrlistat can cause a decrease in the absorption of Amiodarone resulting in a reduced serum concentration and potentially a decrease in efficacy.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.
OsimertinibThe serum concentration of Amiodarone can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Amiodarone.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Amiodarone.
OxprenololAmiodarone may increase the bradycardic activities of Oxprenolol.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Amiodarone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.
OxytocinOxytocin may increase the QTc-prolonging activities of Amiodarone.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Amiodarone.
PalbociclibThe serum concentration of Amiodarone can be increased when it is combined with Palbociclib.
PaliperidoneAmiodarone may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Amiodarone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Amiodarone.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Amiodarone.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Amiodarone.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Amiodarone.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Amiodarone.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Amiodarone.
ParoxetineParoxetine may increase the QTc-prolonging activities of Amiodarone.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Amiodarone.
PasireotideAmiodarone may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.
PazopanibPazopanib may increase the QTc-prolonging activities of Amiodarone.
Peginterferon alfa-2bThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololAmiodarone may increase the bradycardic activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Amiodarone.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Amiodarone.
PentobarbitalThe metabolism of Amiodarone can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Amiodarone.
PerflutrenPerflutren may increase the QTc-prolonging activities of Amiodarone.
PergolideThe metabolism of Pergolide can be decreased when combined with Amiodarone.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Amiodarone.
PermethrinThe metabolism of Permethrin can be decreased when combined with Amiodarone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Amiodarone.
PethidineThe metabolism of Pethidine can be decreased when combined with Amiodarone.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Amiodarone.
PhenforminThe metabolism of Phenformin can be decreased when combined with Amiodarone.
PhenindioneAmiodarone may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Amiodarone can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Amiodarone.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Amiodarone.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Amiodarone.
PhenytoinThe serum concentration of Amiodarone can be decreased when it is combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Amiodarone.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.
PimozidePimozide may increase the QTc-prolonging activities of Amiodarone.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Amiodarone.
PindololAmiodarone may increase the bradycardic activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Amiodarone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Amiodarone.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Amiodarone.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Amiodarone.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Amiodarone.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Amiodarone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Amiodarone.
Poractant alfaAmiodarone may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Amiodarone.
PractololAmiodarone may increase the bradycardic activities of Practolol.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Amiodarone.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Amiodarone resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Amiodarone.
PrazepamThe metabolism of Prazepam can be decreased when combined with Amiodarone.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Amiodarone.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Amiodarone.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amiodarone.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Amiodarone.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Amiodarone.
PrimidoneThe metabolism of Amiodarone can be increased when combined with Primidone.
ProcainamideAmiodarone may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Amiodarone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Amiodarone.
PromazinePromazine may increase the QTc-prolonging activities of Amiodarone.
PromazineThe metabolism of Promazine can be decreased when combined with Amiodarone.
PromethazinePromethazine may increase the QTc-prolonging activities of Amiodarone.
PromethazineThe metabolism of Promethazine can be decreased when combined with Amiodarone.
PropafenonePropafenone may increase the arrhythmogenic activities of Amiodarone.
PropafenoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Amiodarone.
PropofolThe metabolism of Propofol can be decreased when combined with Amiodarone.
PropranololAmiodarone may increase the bradycardic activities of Propranolol.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Amiodarone.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Amiodarone.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amiodarone.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Amiodarone.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Amiodarone.
PyrimethamineThe metabolism of Amiodarone can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Amiodarone.
QuetiapineAmiodarone may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Amiodarone.
QuinidineAmiodarone may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Amiodarone.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Amiodarone.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Amiodarone.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Amiodarone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amiodarone.
RanolazineThe metabolism of Amiodarone can be decreased when combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Amiodarone.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Amiodarone.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Amiodarone.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Amiodarone.
repinotanThe metabolism of repinotan can be decreased when combined with Amiodarone.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Amiodarone.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Amiodarone.
RifabutinThe metabolism of Amiodarone can be increased when combined with Rifabutin.
RifampicinThe serum concentration of the active metabolites of Amiodarone can be reduced when Amiodarone is used in combination with Rifampicin resulting in a loss in efficacy.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Amiodarone.
RifapentineThe metabolism of Amiodarone can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amiodarone.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Amiodarone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Amiodarone.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Amiodarone.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Amiodarone.
RiociguatThe metabolism of Riociguat can be decreased when combined with Amiodarone.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Amiodarone.
RisperidoneRisperidone may increase the QTc-prolonging activities of Amiodarone.
RitonavirThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Amiodarone.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Amiodarone.
RivastigmineRivastigmine may increase the bradycardic activities of Amiodarone.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Amiodarone.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Amiodarone.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amiodarone.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Amiodarone.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Amiodarone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Amiodarone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Amiodarone.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Amiodarone.
RuxolitinibRuxolitinib may increase the bradycardic activities of Amiodarone.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Amiodarone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Amiodarone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Amiodarone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Amiodarone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Amiodarone.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Amiodarone.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Amiodarone.
SecobarbitalThe metabolism of Amiodarone can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Amiodarone.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Amiodarone.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Amiodarone.
SertindoleThe metabolism of Sertindole can be decreased when combined with Amiodarone.
SertralineThe metabolism of Amiodarone can be decreased when combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Amiodarone.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Amiodarone.
SildenafilThe metabolism of Amiodarone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.
SiltuximabThe serum concentration of Amiodarone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Amiodarone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amiodarone.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Amiodarone.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Amiodarone.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Amiodarone.
Sodium Iodide I-131The therapeutic efficacy of Sodium Iodide I-131 can be decreased when used in combination with Amiodarone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Amiodarone.
SofosbuvirSofosbuvir may increase the bradycardic activities of Amiodarone.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amiodarone.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Amiodarone.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Amiodarone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.
SorafenibThe metabolism of Amiodarone can be decreased when combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Amiodarone.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Amiodarone.
SparteineAmiodarone may increase the QTc-prolonging activities of Sparteine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Amiodarone.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Amiodarone.
St. John's WortThe serum concentration of Amiodarone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Amiodarone can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Amiodarone.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Amiodarone.
SulfamethoxazoleThe metabolism of Amiodarone can be decreased when combined with Sulfamethoxazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Amiodarone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Amiodarone.
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Amiodarone.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amiodarone.
SunitinibSunitinib may increase the QTc-prolonging activities of Amiodarone.
SuprofenThe metabolism of Suprofen can be decreased when combined with Amiodarone.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Amiodarone.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Amiodarone.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Amiodarone.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Amiodarone.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Amiodarone.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Amiodarone resulting in a loss in efficacy.
TamoxifenThe metabolism of Amiodarone can be decreased when combined with Tamoxifen.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Amiodarone.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Amiodarone.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Amiodarone.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Amiodarone.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Amiodarone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amiodarone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Amiodarone.
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Amiodarone resulting in a loss in efficacy.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Amiodarone.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Amiodarone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Amiodarone.
TelavancinTelavancin may increase the QTc-prolonging activities of Amiodarone.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Amiodarone.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Amiodarone.
TemazepamThe metabolism of Temazepam can be decreased when combined with Amiodarone.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Amiodarone.
TeniposideThe metabolism of Teniposide can be decreased when combined with Amiodarone.
TenofovirThe metabolism of Amiodarone can be decreased when combined with Tenofovir.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.
TerbinafineThe metabolism of Amiodarone can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Amiodarone.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Amiodarone.
TeriflunomideThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Amiodarone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Amiodarone.
TetrabenazineAmiodarone may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Amiodarone.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Amiodarone.
TheophyllineThe metabolism of Amiodarone can be decreased when combined with Theophylline.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Amiodarone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.
ThioridazineThioridazine may increase the QTc-prolonging activities of Amiodarone.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Amiodarone.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Amiodarone.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Amiodarone.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.
TicagrelorThe metabolism of Amiodarone can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Amiodarone can be decreased when combined with Ticlopidine.
TimololAmiodarone may increase the bradycardic activities of Timolol.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Amiodarone.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Amiodarone.
TipranavirThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Amiodarone.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Amiodarone.
TizanidineTizanidine may increase the bradycardic activities of Amiodarone.
TocilizumabThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Amiodarone.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Amiodarone.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.
TolterodineTolterodine may increase the QTc-prolonging activities of Amiodarone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Amiodarone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amiodarone.
TopiramateThe metabolism of Amiodarone can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amiodarone.
TorasemideThe metabolism of Torasemide can be decreased when combined with Amiodarone.
ToremifeneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Toremifene.
ToremifeneToremifene may increase the QTc-prolonging activities of Amiodarone.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Amiodarone.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Amiodarone.
TranylcypromineThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Amiodarone.
TrazodoneTrazodone may increase the QTc-prolonging activities of Amiodarone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Amiodarone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Amiodarone.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Amiodarone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Amiodarone.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Amiodarone.
TriazolamThe metabolism of Triazolam can be decreased when combined with Amiodarone.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.
TrimethoprimThe metabolism of Amiodarone can be decreased when combined with Trimethoprim.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Amiodarone.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Amiodarone.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Amiodarone.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Amiodarone.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Amiodarone.
UdenafilThe metabolism of Udenafil can be decreased when combined with Amiodarone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amiodarone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Amiodarone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.
Valproic AcidThe metabolism of Amiodarone can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Amiodarone can be decreased when combined with Valsartan.
VandetanibAmiodarone may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Amiodarone.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Amiodarone.
VardenafilVardenafil may increase the QTc-prolonging activities of Amiodarone.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Amiodarone.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Amiodarone.
VemurafenibVemurafenib may increase the QTc-prolonging activities of Amiodarone.
VenlafaxineThe metabolism of Amiodarone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Amiodarone.
VerapamilThe metabolism of Amiodarone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Amiodarone.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Amiodarone.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Amiodarone.
VilanterolVilanterol may increase the QTc-prolonging activities of Amiodarone.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Amiodarone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Amiodarone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Amiodarone.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Amiodarone.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Amiodarone.
VoriconazoleThe metabolism of Amiodarone can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Amiodarone.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Amiodarone.
WarfarinThe metabolism of Warfarin can be decreased when combined with Amiodarone.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Amiodarone.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Amiodarone.
ZafirlukastThe metabolism of Amiodarone can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Amiodarone.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Amiodarone.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Amiodarone.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Amiodarone.
ZileutonThe metabolism of Zileuton can be decreased when combined with Amiodarone.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Amiodarone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Amiodarone.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Amiodarone.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Amiodarone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Amiodarone.
ZuclopenthixolAmiodarone may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wang SP, Wang JA, Luo RH, Cui WY, Wang H: Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1077-84. doi: 10.1111/j.1440-1681.2008.04964.x. Epub 2008 May 25. [PubMed:18505444 ]
  3. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovacs P, Matyus P, Papp JG: Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem. 2004 Jan;11(1):1-11. [PubMed:14754422 ]
  4. Waldhauser KM, Brecht K, Hebeisen S, Ha HR, Konrad D, Bur D, Krahenbuhl S: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Br J Pharmacol. 2008 Oct;155(4):585-95. doi: 10.1038/bjp.2008.287. Epub 2008 Jul 7. [PubMed:18604229 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Doggrell SA, Brown L: Present and future pharmacotherapy for heart failure. Expert Opin Pharmacother. 2002 Jul;3(7):915-30. [PubMed:12083991 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157 ]
  4. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  4. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:14